Cagrilintide | 10mg

Cagrilintide is a long-acting amylin analog currently under investigation as a treatment for obesity and type 2 diabetes. 

Mechanism of Action 

Amylin is a hormone produced by the pancreas that helps regulate appetite and blood sugar levels. Cagrilintide is a synthetic version of amylin that is designed to have a longer half-life and be injected less frequently than natural amylin. 

Cagrilintide works by:

Suppressing appetite, Slowing gastric emptying, and Reducing calorie intake. 

Clinical Trials 

Several clinical trials have evaluated the efficacy and safety of cagrilintide. In one trial, participants with obesity who received cagrilintide lost an average of 10% of their body weight over 26 weeks, compared to 3% in the placebo group. Another trial showed that cagrilintide improved blood sugar control and reduced weight in people with type 2 diabetes. 

Combination Therapy 

Cagrilintide is also being studied in combination with other medications for obesity and diabetes. For example, a study combining cagrilintide with semaglutide, another anti-obesity medication, showed greater weight loss than either medication alone. 

Side Effects 

The most common side effects of cagrilintide include nausea, vomiting, and diarrhea. These side effects are generally mild and tend to improve over time. 

Future Directions

Cagrilintide is a promising new treatment option for obesity and diabetes. Further research is needed to determine the optimal dosage and combination therapies for cagrilintide. It is also important to evaluate its long-term safety and effectiveness. 

 10 mg – Batch CAG10N020525 99.7% purity | 10.97 mg

CAS NO: 1415456-99-3

Molecular Formula: C194H312N54O59S2

Molecular Weight: 4,409 g/mol

Appearance: white powder

Storage: 2-8°

Purity: ≥99

Please note that all products featured here are intended exclusively for research and development purposes. They are not designed for any form of human consumption. These products have not undergone evaluation by the U.S. Food and Drug Administration.